Pharmaceutics International (PII) has secured a contract with Breckenridge to manufacture the firm's generic hormone replacement therapy (HRT) drug.
The Florida-based firm filed with the US Food and Drug Administration (FDA) at the beginning of last year and expects to receive approval and market the product in 2007.No financial details of the deal were disclosed.
Also in the news recently was contract manufacturer Eden Biodesign who has inked two deals in as many weeks.
The most recent was signed this week with the University of Manchester Intellecutal Property (UMIP) - the university's managing agent IP commercialisation. The firm was selected by UMIP to provide a range of services for the development of a drug aimed at treating macular degeneration and cancer.
Eden had just inked another deal with the University of Birmingham under which the Liverpool-based company will develop and produce a novel therapeutic candidate for the treatment of autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
Meanwhile, Laureate Pharma has entered into a manufacturing agreement with Enobia Pharma, a biotech firm specialised in the development of enzyme replacement therapies.
Under the terms of the deal, Laureate will produce Enobia's fusion protein for the treatment of hypophosphatasia - a rare metabolic bone disease characterised by skeletal hypomineralisation. Canada-based Enobia said it expects to start clinical studies of the drug in the summer of 2008..
Also in contract biomanufacturing news, Cytovance Biologics has been selected by Selexys Pharmaceuticals Corporation to provide a range of process development services to support the company's anti-ahesion antibody programmes which are soon to enter the clinic.
Cytovance specialises in the execution of clinical production of antibody and recombinant protein products derived from cell culture at scales up to 500L from both fed-batch and perfusion processes.
The manufacturing of Selexys's engineered humanised antibodies - for the treatment of acute and chronic inflammatory and thrombotic disorders - will be conducted by Cytovance's process development group in Oklahoma City facility.
